Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-202 in Neoadjuvant Prostate Cancer
NCT02381236Phase 2Completed
- Sponsor
- Inspyr Therapeutics
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mipsagargin in prostate cancer (PCa), sponsored by Inspyr Therapeutics. Primary endpoints: Volume of the prostate using multiparametric prostate magnetic resonance imaging (mpMRI) at 12 weeks and Perfusion of the prostate using multiparametric prostate magnetic resonance imaging (mpMRI) at 12 weeks. Started Feb 2016; status: completed.
02
Drugs
mipsagargin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02381236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381236.